Anormed Genzyme Millenium Saga Continues
It will be interesting to see where this story ends. Now Anormed is considering the higher bid from Genzyme and has given Millenium three days to respond.
AnorMED considers higher Genzyme bid superior, gives Millennium 3 days to react - Forbes.com
The above Forbes article has a reasonable synopsis of events but otherwise is very short.
Another article from Bioworld has some insight into the situation.
Genzyme, Now In Front For AnorMED
The whole bidding war seems to be over the drug Mozobil which stimulates the transfer of stem cells from bone marrow into the blood stream, although AnorMED does have some other promising drugs in it’s pipeline.
Technorati Tags: Anormed, Genzyme, Millennium, pharma M&A, pharmaceutical deals, Mozobil
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
